All In Biotech

Drug Trial Radar · NCT00943111

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)

A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)

Last checked: Nov 19, 2026Latest source record: Nov 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

160

Actual

Start

Sep 2009

Primary completion

Nov 2012

Study completion Jun 2015

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Jul 22, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 study was designed to confirm the efficacy and safety of eliglustat tartrate (Genz-112638) in participants with Gaucher disease type 1 who had reached therapeutic goals with enzyme replacement therapy (ERT).

Conditions

  • Gaucher Disease, Type 1

Interventions

  • Eliglustat tartrateDrug

    Primary analysis period (PAP): Eliglustat tartrate capsule 50 milligram (mg) twice daily (BID) orally from Day 1 to Week 4 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 8, and then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 52. Dose adjustments after Week 4 and Week 8 were based on Genz-99067 (active moiety of eliglustat tartrate in plasma) trough plasma concentrations. If Genz-99067 trough plasma concentration was less than (\<) 5 nanogram per milliliter \[ng/mL\] next higher dose was administered whereas if Genz-99067 trough plasma concentration was greater than or equal to (\>=) 5 ng/mL same dose was continued. Pharmacokinetic (PK) assessment at Week 2 and 6 were used for dose adjustment after Week 4 and Week 8, respectively. Long-term treatment period (LTTP): Participants originally randomized to eliglustat in PAP continued to receive eliglustat dose, based on their Genz 99067 plasma trough concentration at Week 6.

  • ImigluceraseDrug

    PAP: Imiglucerase intravenous infusion every other week (q2w) up to Week 52 in doses equivalent to participant's past ERT dose prior to any unanticipated treatment interruption, dose reduction, or regimen change. LTTP: Participants originally randomized to imiglucerase received eliglustat tartrate capsule 50 mg BID orally from Week 52+1 Day to Week 56 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 60, and then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to 5 years. The dose adjustments after Week 56 and Week 60 were based on Genz-99067 (active moiety of eliglustat tartrate in plasma) trough plasma concentrations. If Genz-99067 trough plasma concentration was \<5 ng/mL the next higher dose was administered whereas if the Genz-99067 trough plasma concentration was \>=5 ng/mL the same dose was continued. The PK assessment at Week 54 and Week 58 were used for dose adjustment after Week 56 and Week 60, respectively.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Remained Stable for 52 Weeks During the Primary Analysis PeriodTime frame: Baseline up to Week 52
  2. Percentage of Participants Who Remained Stable Annually for 4 Years During the LTTPTime frame: Week 52 up to week 208

Locations

34 sites in 12 countries. Site status is shown where the registry gives one.

  • Tower Hematology Oncology Medical Group

    Beverly Hills, California

  • UCSF MS Center

    San Francisco, California

  • University of Colorado Health Science Center - Aurora

    Aurora, Colorado

  • Yale University School of Medicine

    New Haven, Connecticut

  • Northwest Oncology Hematology Associates PA

    Coral Springs, Florida

  • Emory University Medical Genetics

    Decatur, Georgia

  • Children's Memorial Hospital

    Chicago, Illinois

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • Albany Medical Center

    Albany, New York

  • North Shore University Medical Center

    Manhasset, New York

  • Mount Sinai School of Medicine

    New York, New York

  • New York University School of Medicine

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • O and O Alpan LLC

    Springfield, Virginia

  • Hospital General de Agudos J.M Ramos Mejia

    Buenos Aires, Argentina

  • Hospital General de Ninos Dr. Ricardo Gutierrez

    Buenos Aires, Argentina

  • Royal Perth Hospital

    Perth, WA, Australia

  • Hospital de Clinicas da Universidade Federal do Parana

    Curitiba, Brazil

  • Instituto de Estadual de Hematologia Arthur de Siqueria Cavalcanti

    Rio de Janeiro, Brazil

  • IGEIM

    São Paulo, Brazil

  • Mount Sinai Hospital and the Samuel Lunenfeld Research Institute

    Toronto Ontario, Canada

  • Abou El Reesh Children's University Hospital (El Mounira), Faculty of Medicine (Kasr Al-Aini), Cairo University Hospitals, El Mounira, Cairo, Egypt

    Cairo, Egypt

  • Hôpital Beaujon

    Clichy, France

  • Charité Universitätsmedizin Berlin

    Berlin, Germany

  • Asklepios Klinik St. Georg

    Hamburg, Germany

  • Katholische Kliniken Oberhausen gem. GmbH

    Oberhausen, Germany

  • Azienda Ospedaliero Universitaria Careggi

    Florence, Italy

  • Azienda Ospedialiero-Universitaria S. Maria Della Misericordia

    Udine, Italy

  • Hematology Research Center of Ministry of Healthcare of the Russian Federation

    Moscow, Russia

  • Hospital University Miguel Servet

    Zaragoza, Spain

  • Cambridge University Hosptials, Addenbrookes Hospital

    Cambridge, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.